United States, Las Vega (Nevada) //— As per DelveInsight’s assessment, globally, about 75+ key pharma and biotech companies are working on 75+ pipeline drugs in the Major Depressive Disorder therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
Biomarkers are measurable indicators that could help diagnose Major Depressive Disorder or predict treatment response. Therapies based on nociceptin receptor antagonists, Botox, and selective orexin 2 receptor antagonist are currently under development. If these therapies are successfully approved and commercialized, they have the potential to transform the current standard of care for Major Depressive Disorder (MDD) patients.
“Major Depressive Disorder Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Major Depressive Disorder Market.
The Major Depressive Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Major Depressive Disorder Pipeline Analysis
The report provides insights into:
– The report provides detailed insights about emerging therapies for the treatment of Major Depressive Disorder and the aggregate therapies developed by major pharma companies.
– It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Major Depressive Disorder Treatment.
– It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
– The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
– It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Major Depressive Disorder market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Delveinsight’s Report Covers 75+ Emerging Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage products (Phase I/II and Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates
Major Depressive Disorder Therapeutics Landscape
Psychological treatments (also known as talking therapies) are an effective way to treat depression. This therapy can help patients change their thinking patterns and improve coping skills, so they are better equipped to deal with life’s stresses and conflicts. As well as supporting recovery, psychological therapies can help to stay well by identifying and changing unhelpful thoughts and behavior.
There are approx. 75+ key companies which are developing therapies for Major Depressive Disorder. Currently, SAGE Therapeutics is leading the Major Depressive Disorder therapeutics segment, with its drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Major Depressive Disorder Therapeutic Market include:
GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, Axsome Therapeutics, Johnson & Johnson, and many others.
Major Depressive Disorder Emerging Drugs Covered in the Report include:
• SAGE-217: Sage Therapeutics
• REL-1017: Relmada Therapeutics, Inc
• Seltorexant: Minerva Sciences
• SP-624: Sirtsei Pharmaceuticals, Inc.
• SPL026: Small Pharma
• PDC-1421: BioLite Inc
And many more
Explore More About the Emerging Drugs and Key Companies: Major Depressive Disorder Pipeline Development Activities
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Major Depressive Disorder Current Treatment Patterns
4. Major Depressive Disorder – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Major Depressive Disorder Late-Stage Products (Phase-III)
7. Major Depressive Disorder Mid-Stage Products (Phase-II)
8. Major Depressive Disorder Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Major Depressive Disorder Discontinued Products
13. Major Depressive Disorder Product Profiles
14. Key Companies in the Major Depressive Disorder Market
15. Key Products in the Major Depressive Disorder Therapeutics Segment
16. Dormant and Discontinued Products
17. Major Depressive Disorder Unmet Needs
18. Major Depressive Disorder Future Perspectives
19. Major Depressive Disorder Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Get a Detailed Assessment into the Ongoing Clinical and Regulatory Development Activities, at: Major Depressive Disorder Therapeutic Outlook
Contact Info:
Shruti Thakur
Manager (Marketing and Branding)
Email: info@delveinsight.com
https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
